---
document_datetime: 2023-09-21 18:03:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/mabcampath-epar-procedural-steps-taken-authorisation_en.pdf
document_name: mabcampath-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4542372
conversion_datetime: 2025-12-18 23:27:05.314306
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

•

<!-- image -->

Medicinal product no longer authorise The company Millenium &amp; ILEX UK Ltd. submitted on 23 March 2000 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for MabCampath, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. J. Ersbøll Co-Rapporteur: Prof. S. Garattini Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 14 April 2000. · The  applicant  received  Scientific  Advice  from  the  CPMP  on  25  February  1998  and  on  14 September 1998. The Scientific Advice pertained to parts II, III and IV of the dossier. · The Rapporteur's first Assessment Report was circulated to all CPMP members on 22 June 2000 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP Members on 22 June 2000 (Annex 2) · During the meeting on 25-27 July 2000 the CPMP agreed on the consolidated List of Questions to be sent to the company. The final consolidated List of Questions was sent to the company on 27 July 2000 (Annex 3). · The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  22 November 2000. · The summary report of the GCP inspection carried out at the manufacturing sites between 28 December 2000-3 January 2001 of the M &amp; I UK Ltd The Surrey Research Park, Guildford, and Surrey was issued on 18 January 2001 (Annex 4). · The  Rapporteur  and Co-Rapporteur  circulated the response Assessment  Report  on  the company's  responses  to  the  List  of  Questions  to  all  CPMP  members  on  10  January  2001 (Annex 5) · A list  of  outstanding  issues  to  be  addressed  in  writing  and  during  an  oral  explanation  by  the Applicant was adopted by the CPMP on 23 January 2001. · The company submitted the responses to the CPMP request for supplementary information on 12 February 2001. During the meeting on 27 February-01 March the CPMP discussed the applicant's responses to the outstanding issues and considered that an oral explanation was not necessary. The CPMP requested from the applicant a proposal for further clinical development of MabCampath. During the meeting on 27-29 March 2001 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to MabCampath on 28 March 2001.